Table 2.

Univariate analysis of outcomes

	No-EMD (N = 8983)		EMD (N = 814)		EMD and MD at HCT
Outcomes‡	N Eval	Prob (95% CI)	N Eval	Prob (95% CI)	N Eval	Prob (95% CI)
Acute GVHD, grade II–IV	8938		811		61
100-day		36 (35–37)%		35 (32–38)%		38 (26–51)%
Chronic GVHD	8712		793		59
1-year		41 (40–42)%		42 (38–45)%		25 (14–38)%
3-year		45 (44–46)%		45 (42–49)%		28 (16–41)%
5-year		46 (44–47)%		46 (42–49)%		28 (16–41)%
Relapse	8877		804		60
1-year		29 (28–29)%		33 (30–37)%		58 (45–70)%
3-year		34 (33–35)%		39 (36–43)%		62 (48–73)%
5-year		36 (35–37)%		41 (37–44)%		62 (48–73)%
Treatment related mortality	8877		804		60
1-year		24 (23–25)%		20 (18–23)%		25 (15–37)%
3-year		29 (28–30)%		24 (21–27)%		29 (18–41)%
5-year		31 (30–32)%		26 (23–29)%		35 (22–48)%
Leukemia free survival	8877		804		60
1-year		48 (47–49)%		46 (43–50)%		17 (8–27)%
3-year		37 (36–38)%		37 (33–40)%		9 (3–18)%
5-year		33 (32–34)%		33 (30–37)%		NE†
Overall survival	8983		814		61
1-year		54 (53–55)%		53 (50–57)%		21 (12–32)%
3-year		40 (39–41)%		40 (37–44)%		10 (4–20)%
5-year		35 (34–37)%		36 (32–39)%		5 (1–13)%

^†No case at risk at this time point

^‡Gray’s test: p=0.92 for aGVHD, p=0.21 for cGVHD, p<0.001 for relapse, p=0.031 for TRM.

Log-rank test: p<0.001 for DFS, p<0.001 for OS